SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Kronstrand Robert)
 

Sökning: WFRF:(Kronstrand Robert) > Identification of A...

Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry

Castaneto, Marisol S. (författare)
NIDA, MD 21224 USA; University of Maryland, MD 21201 USA
Wohlfarth, Ariane (författare)
NIDA, MD 21224 USA
Pang, Shaokun (författare)
SCIEX Ltd, CA USA
visa fler...
Zhu, Mingshe (författare)
Bristol Myers Squibb Co, NJ USA
Scheidweiler, Karl B. (författare)
NIDA, MD 21224 USA
Kronstrand, Robert (författare)
Linköpings universitet,Medicinska fakulteten,Avdelningen för läkemedelsforskning,Natl Board Forens Med, Dept Forens Genet and Forens Toxicol, Linkoping, Sweden
Huestis, Marilyn A. (författare)
NIDA, MD 21224 USA
visa färre...
 (creator_code:org_t)
2015-04-21
2015
Engelska.
Ingår i: Forensic Toxicology. - : Springer Verlag (Germany). - 1860-8965 .- 1860-8973. ; 33:2, s. 295-310
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • AB-FUBINACA, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, is an indazole synthetic cannabinoid identified in drug seizures around the world. Few metabolism data are available, despite the need for human urinary markers to detect AB-FUBINACA intake. Our main objective was to identify suitable analytical targets by analyzing human hepatocyte incubation samples with high-resolution mass spectrometry (HRMS) and to confirm the results in authentic urine specimens. We also determined AB-FUBINACAs metabolic stability in human liver microsomes (HLMs) and compared hepatocyte and urine results with in silico predictions. The metabolic stability of AB-FUBINACA was determined in pooled HLMs (1 A mu mol/l, up to 1 h). The metabolite profile of human hepatocytes (10 A mu mol/l, 1 and 3 h) and urine samples from two subjects were determined by HRMS using information-dependent tandem-mass spectrometry (MS-MS) acquisition. Data were analyzed with MetabolitePilot (TM) software utilizing different processing algorithms, including generic peak finding, mass defect filtering, neutral loss, and product ion filtering. In silico metabolite prediction was performed with MetaSite (TM) software. AB-FUBINACAs half-life in HLMs was 62.6 +/- A 4.0 min. AB-FUBINACA produced 11 metabolites (2 glucuronides) in human hepatocytes and 10 were identified in authentic human urine. Major metabolic pathways were terminal amide hydrolysis, acyl glucuronidation and hydroxylation at the aminooxobutane moiety. Epoxidation followed by hydrolysis, hydroxylation at the indazole moiety and dehydrogenation were minor pathways. Defluorination did not occur. Seventeen first-generation metabolites were predicted in silico, of which seven were observed in vitro and eight in vivo. We recommend AB-FUBINACA carboxylic acid, hydroxy AB-FUBINACA carboxylic acid, dihydrodiol AB-FUBINACA and dihydrodiol AB-FUBINACA carboxylic acid as suitable urinary markers.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

AB-FUBINACA; Metabolite profiling; HRMS; Hepatocytes; In silico

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy